Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib
Aicardi-Goutières syndrome (AGS) is a rare hereditary early-onset encephalopathy. The syndrome was first described in 1984, and is characterised by upregulation of the type I interferon (IFN) pathway, which is involved in the host immune response against viral infections, including SARS-CoV-2. Whils...
Main Authors: | Abirami Pararajasingam, Rachel E. Bradley, Jennifer Evans, Ashima Lowe, Richard Goodwin, Stephen Jolles |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.837568/full |
Similar Items
-
Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
by: Marco Cattalini, et al.
Published: (2021-10-01) -
Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib
by: Wei Wang, et al.
Published: (2023-10-01) -
Characterization of a mutant samhd1 zebrafish model implicates dysregulation of cholesterol biosynthesis in Aicardi-Goutières syndrome
by: Sarah E. Withers, et al.
Published: (2023-03-01) -
Misdiagnosed Aicardi Goutières Syndrome Patient: A Case Report
by: Mohammad Moein Vakilzadeh, et al.
Published: (2021-10-01) -
Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi–Goutières Syndrome Phenotype
by: Isabella Peixoto de Barcelos, et al.
Published: (2023-08-01)